PEG-conjugated bovine haemoglobin enhances efficiency of chemotherapeutic agent doxorubicin with alleviating DOX-induced splenocardiac toxicity in the breast cancer

References

• Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014;10(4):853–858.
   PubMed Web of Science ®Google Scholar
• Tacar O, Dass CR. Doxorubicin-induced death in tumour cells and cardiomyocytes: is autophagy the key to improving future clinical outcomes? J Pharm Pharmacol. 2013;65(11):1577–1589.
   PubMed Web of Science ®Google Scholar
• Cardano M, Tribioli C, Prosperi E. Targeting proliferating cell nuclear antigen (PCNA) as an effective strategy to inhibit tumor cell proliferation. Curr Cancer Drug Targets. 2020;20(4):240–252.
   PubMed Web of Science ®Google Scholar
• Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol. 2012;124(6):763–775.
   PubMed Web of Science ®Google Scholar
• Wei X, Chen Y, Jiang X, et al. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Mol Cancer. 2021;20(1):7.
   PubMed Web of Science ®Google Scholar
• Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao L, Li XF. Hypoxia and the tumor microenvironment. Technol Cancer Res Treat. 2021;20:15330338211036304.
   Web of Science ®Google Scholar
• Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine. 2018;13:6049–6058.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225–239.
   PubMed Web of Science ®Google Scholar
• Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003;195(1):1–16.
   PubMed Web of Science ®Google Scholar
• Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93(4):266–276.
   PubMedGoogle Scholar
• Wu BB, Leung KT, Poon EN. Mitochondrial-Targeted therapy for doxorubicin-induced cardiotoxicity. Int J Mol Sci. 2022;23(3):1912. doi: 10.3390/ijms23031912. PMID: 35163838; PMCID: PMC8837080.
   Web of Science ®Google Scholar
• Shafei A, El-Bakly W, Sobhy A, et al. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 2017;95:1209–1218.
   PubMed Web of Science ®Google Scholar
• Poljaková J, Eckschlager T, Hřebačková J, et al. The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells. Interdiscip Toxicol. 2008;1(2):186–189.
   PubMedGoogle Scholar
• Baxter-Holland M, Dass CR. Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use. J Pharm Pharmacol. 2018;70(3):320–327.
   PubMed Web of Science ®Google Scholar
• Bao MH, Wong CC. Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. Cells. 2021;10(7):1715.
   PubMed Web of Science ®Google Scholar
• Jansman MMT, Liu X, Kempen P, et al. Hemoglobin-Based oxygen carriers incorporating nanozymes for the depletion of reactive oxygen species. ACS Appl Mater Interfaces. 2020;12(45):50275–50286.
   PubMed Web of Science ®Google Scholar
• Dai M, Yu M, Han J, et al. PEG-conjugated hemoglobin combination with cisplatin enforced the antiangiogeic effect in a cervical tumor xenograft model. Artif Cells Blood Substit Immob Biotechnol. 2008;36(6):487–497.
   PubMed Web of Science ®Google Scholar
• Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994;13(2):139–168.
   PubMed Web of Science ®Google Scholar
• Lucas A, Belcher DA, Munoz C, et al. Polymerized human hemoglobin increases the effectiveness of cisplatin-based chemotherapy in non-small cell lung cancer. Oncotarget. 2020;11(42):3770–3781.
   PubMedGoogle Scholar
• Jadapalli JK, Wright GW, Kain V, et al. Doxorubicin triggers splenic contraction and irreversible dysregulation of COX and LOX that alters the inflammation-resolution program in the myocardium. Am J Physiol Heart Circulat Physiol. 2018;315(5):h1091–h1100.
   PubMed Web of Science ®Google Scholar
• Songbo M, Lang H, Xinyong C, et al. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett. 2019;307:41–48.
   PubMed Web of Science ®Google Scholar
• Bhagat A, Kleinerman ES. Anthracycline-Induced cardiotoxicity: causes, mechanisms, and prevention. Adv Exp Med Biol. 2020;1257:181–192.
   PubMed Web of Science ®Google Scholar
• Rawat PS, Jaiswal A, Khurana A, et al. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708.
   PubMed Web of Science ®Google Scholar
• Sheibani M, Azizi Y, Shayan M, et al. Doxorubicin-Induced cardiotoxicity: an overview on pre-clinical therapeutic approaches. Cardiovasc Toxicol. 2022;22(4):292–310.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P, Jr., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–717.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Hussey MA, Moinpour CM, et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on southwest oncology group protocol s8897. J Clin Oncol. 2008;26(8):1223–1230.
   PubMed Web of Science ®Google Scholar
• Avagimyan A, Mkrtchyan L, Abrahomovich O, et al. AC-Mode of chemotherapy as a trigger of cardiac syndrome X: a case study. Curr Probl Cardiol. 2022;47(9):100994.
   PubMed Web of Science ®Google Scholar
• Ludke AR, Al-Shudiefat AA, Dhingra S, et al. A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Can J Physiol Pharmacol. 2009;87(10):756–763.
   PubMed Web of Science ®Google Scholar
• Abdulkareem Aljumaily SA, Demir M, Elbe H, et al. Antioxidant, anti-inflammatory, and anti-apoptotic effects of crocin against doxorubicin-induced myocardial toxicity in rats. Environ Sci Pollut Res Int. 2021;28(46):65802–65813.
   PubMed Web of Science ®Google Scholar
• Traverso N, Ricciarelli R, Nitti M, et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev. 2013;2013:972913.
   PubMed Web of Science ®Google Scholar
• Xie G, Dong H, Liang Y, et al. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.
   PubMed Web of Science ®Google Scholar
• Chu Z, Wang Y, You G, et al. The P(50) value detected by the oxygenation-dissociation analyser and blood gas analyser. Artif Cells Nanomed Biotechnol. 2020;48(1):867–874.
   PubMed Web of Science ®Google Scholar
• Oksenberg D, Dufu K, Patel MP, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016;175(1):141–153.
   PubMed Web of Science ®Google Scholar
• Auerswald S, Schreml S, Meier R, et al. Wound monitoring of pH and oxygen in patients after radiation therapy. Radiat Oncol. 2019;14(1):199.
   PubMed Web of Science ®Google Scholar
• Webster KD, Dahhan D, Otto AM, et al. “Inside-out" PEGylation of bovine β-cross-linked hemoglobin. Artif Organs. 2017;41(4):351–358.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang L, Yu W, et al. A PEGylated bovine hemoglobin as a potent hemoglobin-based oxygen carrier. Biotechnol Prog. 2017;33(1):252–260.
   PubMed Web of Science ®Google Scholar
• Hu T, Prabhakaran M, Acharya SA, et al. Influence of the chemistry of conjugation of poly(ethylene glycol) to Hb on the oxygen-binding and solution properties of the PEG-Hb conjugate. Biochem J. 2005;392(Pt 3):555–564.
   PubMedGoogle Scholar
• Kuo LJ, Yang LX. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo. 2008;22(3):305–309.
   PubMed Web of Science ®Google Scholar
• Huang X, Traganos F, Darzynkiewicz Z. DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis. Cell Cycle. 2003;2(6):613–618.
   Web of Science ®Google Scholar
• Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157–170.
   PubMed Web of Science ®Google Scholar
• Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma. 2018;127(2):175–186.
   PubMed Web of Science ®Google Scholar
• Iyer AK, Singh A, Ganta S, et al. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev. 2013;65(13–14):1784–1802.
   PubMed Web of Science ®Google Scholar
• Wang P, Li X, Yao C, et al. Orthogonal near-infrared upconversion co-regulated site-specific O(2) delivery and photodynamic therapy for hypoxia tumor by using red blood cell microcarriers. Biomaterials. 2017;125:90–100.
   PubMed Web of Science ®Google Scholar
• Yoh K, Ishii G, Yokose T, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res. 2004;10(5):1691–1697.
   PubMed Web of Science ®Google Scholar
• Baekelandt MM, Holm R, Nesland JM, et al. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 2000;20(2B):1061–1067.
   PubMed Web of Science ®Google Scholar
• Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42(1):59–98.
   PubMed Web of Science ®Google Scholar
• Rosso F, Quagliariello V, Tortora C, et al. Cross-linked hyaluronic acid Sub-micron particles: in vitro and in vivo biodistribution study in cancer xenograft model, journal of materials science. J Mater Sci Mater Med. 2013;24(6):1473–1481.
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Hagio M, Ishiwata T. Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. World J Gastroenterol. 2013;19(1):42–48.
   PubMed Web of Science ®Google Scholar
• Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. European Journal of Cancer. 2000;36(6):748–753.
   PubMed Web of Science ®Google Scholar
• Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77(5):858–863.
   PubMed Web of Science ®Google Scholar
• Wehland M, Bauer J, Magnusson NE, et al. Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci. 2013;14(5):9338–9364.
   PubMed Web of Science ®Google Scholar
• Woollard DJ, Opeskin K, Coso S, et al. Differential expression of VEGF ligands and receptors in prostate cancer. Prostate. 2013;73(6):563–572.
   PubMed Web of Science ®Google Scholar
• Ebos JM, Tran J, Master Z, et al. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res. 2002;1(2):89–95.
   PubMed Web of Science ®Google Scholar
• Hansen S, Grabau DA, Rose C, et al. Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab Invest. 1998;78(12):1563–1573.
   PubMed Web of Science ®Google Scholar
• Basilio-de-Oliveira RP, Pannain VL. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors. World J Gastroenterol. 2015;21(22):6924–6930.
   PubMed Web of Science ®Google Scholar
• Majchrzak K, Kaspera W, Szymaś J, et al. Markers of angiogenesis (CD31, CD34, rCBV) and their prognostic value in low-grade gliomas. Neurol Neurochir Pol. 2013;47(4):325–331.
   PubMed Web of Science ®Google Scholar
• Saad RS, El-Gohary Y, Memari E, et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol. 2005;36(9):955–961.
   PubMed Web of Science ®Google Scholar
• Saad RS, Lindner JL, Liu Y, et al. Lymphatic vessel density as prognostic marker in esophageal adenocarcinoma. Am J Clin Pathol. 2009;131(1):92–98.
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–2879.
   PubMed Web of Science ®Google Scholar
• Fornari FA, Randolph JK, Yalowich JC, et al. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994;45(4):649–656.
   PubMed Web of Science ®Google Scholar
• Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J Drug Target. 1996;4(3):129–140.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The provincial systemic treatment disease site group. Cancer Prev Control. 1999;3(2):145–159.
   PubMedGoogle Scholar
• Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12(4):339.
   PubMed Web of Science ®Google Scholar
• Gholami S, Hosseini MJ, Jafari L, et al. Mitochondria as a target for the cardioprotective effects of Cydonia oblonga mill. and Ficus carica L. in doxorubicin-Induced cardiotoxicity. Drug Res. 2017;67(6):358–365.
   Google Scholar
• Varga ZV, Ferdinandy P, Liaudet L, et al. Drug-induced mitochondrial dysfunction and cardiotoxicity, American journal of physiology. Am J Physiol Heart Circ Physiol. 2015;309(9):H1453–1467.
   PubMed Web of Science ®Google Scholar
• Szenczi O, Kemecsei P, Holthuijsen MF, et al. Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem Pharmacol. 2005;69(5):725–732.
   PubMed Web of Science ®Google Scholar
• Minotti G, Recalcati S, Menna P, et al. Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol. 2004;378:340–361.
   PubMed Web of Science ®Google Scholar
• De Beer EL, Bottone AE, Voest EE. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. Eur J Pharmacol. 2001;415(1):1–11.
   PubMed Web of Science ®Google Scholar
• Ascensão A, Magalhães J, Soares JM, et al. Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis. Am J Physiol Heart Circ Physiol. 2005;289(2):H722–731.
   PubMed Web of Science ®Google Scholar
• Sun Z, Yan B, Yu WY, et al. Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a. Exp Ther Med. 2016;12(3):1879–1884.
   PubMed Web of Science ®Google Scholar
• Cesta MF. Normal structure, function, and histology of the spleen. Toxicol Pathol. 2006;34(5):455–465.
   PubMed Web of Science ®Google Scholar
• Halade GV, Norris PC, Kain V, et al. Splenic leukocytes define the resolution of inflammation in heart failure. Sci Signaling. 2018;11(520):eaao1818. doi: 10.1126/scisignal.aao1818. PMID: 29511119; PMCID: PMC6145858.
   PubMed Web of Science ®Google Scholar
• Perez OA, Yeung ST, Vera-Licona P, et al. CD169(+) macrophages orchestrate innate immune responses by regulating bacterial localization in the spleen. Sci Immunol. 2017;2(16):eaah5520. doi: 10.1126/sciimmunol.aah5520. PMID: 28986418; PMCID: PMC5969998.
   PubMed Web of Science ®Google Scholar
• Kalivendi SV, Kotamraju S, Zhao H, et al. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem. 2001;276(50):47266–47276.
   PubMed Web of Science ®Google Scholar
• Ding XZ, Hennig R, Adrian TE. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol Cancer. 2003;2:10.
   PubMedGoogle Scholar
• Ahmed F, Urooj A. Cardioprotective activity of standardized extract of ficus racemosa stem bark against doxorubicin-induced toxicity. Pharm Biol. 2012;50(4):468–473.
   PubMed Web of Science ®Google Scholar
• Ingle KA, Kain V, Goel M, et al. Cardiomyocyte-specific Bmal1 deletion in mice triggers diastolic dysfunction, extracellular matrix response, and impaired resolution of inflammation. Am J Physiol Heart Circulat Physiol. 2015;309:H1827–1836.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Panda BP, Kohli K, et al. Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model. Pharm Biol. 2017;55:1295–1303.
   PubMed Web of Science ®Google Scholar